Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891465150> ?p ?o ?g. }
- W2891465150 endingPage "215" @default.
- W2891465150 startingPage "207" @default.
- W2891465150 abstract "We investigated the association between CYP2C19 genotype and additional effect of cilostazol on clopidogrel resistance (CR) in neuroendovascular therapy. Between January 2012 and January 2016, 447 consecutive patients were administered with 75-mg cilostazol/day. The VerifyNow System was used for evaluating P2Y12 reaction units (PRU) > 230 and/or percentage inhibition of platelet function (% Inhibition) ≤ 20 as CR. Among 158 patients with CR, 31 were administered with additional 100- or 200-mg cilostazol/day and their platelet function was evaluated. According to CYP2C19 genotypes revealed using the Spartan RX and DNeasy Blood & Tissue Kit, patients were classified into three phenotypic groups: extensive metabolizer (EM, three patients), intermediate metabolizer (IM, 12 patients), and poor metabolizer (PM, 16 patients). Administration of additional cilostazol decreased PRU (EM group: 160.7 ± 85.2 after vs 278.3 ± 40.1 before, P = 0.15; IM group: 205.6 ± 74.0 vs 254.3 ± 35.0, P = 0.02; and PM group: 227.8 ± 52.2 vs 282.1 ± 30.4, P = 0.003), and increased % Inhibition (EM group: 40.0 ± 27.9 vs 9.3 ± 3.8, P = 0.25; IM group: 31.4 ± 18.0 vs 11.8 ± 8.2, P = 0.001; and PM group: 24.6 ± 15.0 vs 10.4 ± 9.3, P = 0.001). However, the rate of normalized-clopidogrel response, thromboembolic lesions, and bleeding complications were not significantly different among the three groups. Thus, the addition of cilostazol was effective on CR in terms of PRU, % Inhibition, rate of change of normalized-clopidogrel response, thromboembolic events, and bleeding complications irrespective of phenotype." @default.
- W2891465150 created "2018-09-27" @default.
- W2891465150 creator A5008951441 @default.
- W2891465150 creator A5020493093 @default.
- W2891465150 creator A5024316557 @default.
- W2891465150 creator A5031314236 @default.
- W2891465150 creator A5054600758 @default.
- W2891465150 creator A5054629008 @default.
- W2891465150 creator A5054742065 @default.
- W2891465150 creator A5062301176 @default.
- W2891465150 creator A5067769646 @default.
- W2891465150 creator A5074635182 @default.
- W2891465150 creator A5075186471 @default.
- W2891465150 creator A5086141410 @default.
- W2891465150 creator A5090483556 @default.
- W2891465150 creator A5091649164 @default.
- W2891465150 date "2018-05-01" @default.
- W2891465150 modified "2023-10-04" @default.
- W2891465150 title "Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy." @default.
- W2891465150 cites W1541215435 @default.
- W2891465150 cites W1919067319 @default.
- W2891465150 cites W1972045176 @default.
- W2891465150 cites W1975637962 @default.
- W2891465150 cites W1990228066 @default.
- W2891465150 cites W1991270018 @default.
- W2891465150 cites W1993518253 @default.
- W2891465150 cites W2001759058 @default.
- W2891465150 cites W2007242643 @default.
- W2891465150 cites W2012802578 @default.
- W2891465150 cites W2028938803 @default.
- W2891465150 cites W2029849926 @default.
- W2891465150 cites W2081100231 @default.
- W2891465150 cites W2082149672 @default.
- W2891465150 cites W2105489963 @default.
- W2891465150 cites W2115855594 @default.
- W2891465150 cites W2121960517 @default.
- W2891465150 cites W2149328140 @default.
- W2891465150 cites W2157833432 @default.
- W2891465150 cites W2160599145 @default.
- W2891465150 cites W2170647283 @default.
- W2891465150 cites W2176368539 @default.
- W2891465150 cites W2322786744 @default.
- W2891465150 cites W2464406032 @default.
- W2891465150 cites W2516645969 @default.
- W2891465150 cites W2520469802 @default.
- W2891465150 cites W2591717879 @default.
- W2891465150 cites W27443843 @default.
- W2891465150 doi "https://doi.org/10.18999/nagjms.80.2.207" @default.
- W2891465150 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5995740" @default.
- W2891465150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29915438" @default.
- W2891465150 hasPublicationYear "2018" @default.
- W2891465150 type Work @default.
- W2891465150 sameAs 2891465150 @default.
- W2891465150 citedByCount "4" @default.
- W2891465150 countsByYear W28914651502019 @default.
- W2891465150 countsByYear W28914651502020 @default.
- W2891465150 countsByYear W28914651502021 @default.
- W2891465150 countsByYear W28914651502023 @default.
- W2891465150 crossrefType "journal-article" @default.
- W2891465150 hasAuthorship W2891465150A5008951441 @default.
- W2891465150 hasAuthorship W2891465150A5020493093 @default.
- W2891465150 hasAuthorship W2891465150A5024316557 @default.
- W2891465150 hasAuthorship W2891465150A5031314236 @default.
- W2891465150 hasAuthorship W2891465150A5054600758 @default.
- W2891465150 hasAuthorship W2891465150A5054629008 @default.
- W2891465150 hasAuthorship W2891465150A5054742065 @default.
- W2891465150 hasAuthorship W2891465150A5062301176 @default.
- W2891465150 hasAuthorship W2891465150A5067769646 @default.
- W2891465150 hasAuthorship W2891465150A5074635182 @default.
- W2891465150 hasAuthorship W2891465150A5075186471 @default.
- W2891465150 hasAuthorship W2891465150A5086141410 @default.
- W2891465150 hasAuthorship W2891465150A5090483556 @default.
- W2891465150 hasAuthorship W2891465150A5091649164 @default.
- W2891465150 hasConcept C126322002 @default.
- W2891465150 hasConcept C140840227 @default.
- W2891465150 hasConcept C2777628954 @default.
- W2891465150 hasConcept C2777849778 @default.
- W2891465150 hasConcept C2779820409 @default.
- W2891465150 hasConcept C49059817 @default.
- W2891465150 hasConcept C526171541 @default.
- W2891465150 hasConcept C62231903 @default.
- W2891465150 hasConcept C71924100 @default.
- W2891465150 hasConcept C89560881 @default.
- W2891465150 hasConcept C90924648 @default.
- W2891465150 hasConcept C98274493 @default.
- W2891465150 hasConceptScore W2891465150C126322002 @default.
- W2891465150 hasConceptScore W2891465150C140840227 @default.
- W2891465150 hasConceptScore W2891465150C2777628954 @default.
- W2891465150 hasConceptScore W2891465150C2777849778 @default.
- W2891465150 hasConceptScore W2891465150C2779820409 @default.
- W2891465150 hasConceptScore W2891465150C49059817 @default.
- W2891465150 hasConceptScore W2891465150C526171541 @default.
- W2891465150 hasConceptScore W2891465150C62231903 @default.
- W2891465150 hasConceptScore W2891465150C71924100 @default.
- W2891465150 hasConceptScore W2891465150C89560881 @default.
- W2891465150 hasConceptScore W2891465150C90924648 @default.
- W2891465150 hasConceptScore W2891465150C98274493 @default.
- W2891465150 hasIssue "2" @default.